Key facts
- This page summarizes Ryan Dunlap's Form 4 filing for CytoDyn Inc. (CYDY).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 30 Oct 2024, 21:46.
Ryan Dunlap - 28 Oct 2024 Form 4 Insider Report for CytoDyn Inc. (CYDY)
- Reporting relationship
- Director
- Issuer ticker
- CYDY
- Reported as of
- 28 Oct 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 30 Oct 2024, 21:46:22 UTC
- Prior SEC filing
- 05 Jan 2024
- Next SEC filing
- 24 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tyler Blok, Attorney-in-Fact for Ryan Dunlap
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ryan Dunlap filed Form 4 for CytoDyn Inc. (CYDY) on 30 Oct 2024.
Change
- Previous filing in this sequence was filed on 05 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CYDY
transaction
Derivative
Non-qualified stock option (right to buy)
Award
- Transaction value
- $0
- Shares
- +800,000
- Change %
- Price
- $0.000000
- Shares after
- 800,000
- Date
- 28 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 800,000
- Exercise price
- $0.1300
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This grant was approved by the Company's Compensation Committee on October 28, 2024 and represents the annual grant awarded to the individual for fiscal year 2025. This award is made consistent with, and utilizes shares from, the Issuer's 2012 Equity Incentive Plan, as amended.
Footnote F2
266,664 shares vested on the grant date, and the balance will vest in equal monthly installments at the conclusion of each month of Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended) from October 2024 through May 2025.
SEC remarks
EX 24 - Power of Attorney